Cancer Family
Thoracic Neoplasm
CI-CAN-00000054Explore in graph →
Non-malignant2,893 active trials51 approved drugs626 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000054Explore in graph →
Clinical trials
12,163 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04542369 | Pilot Study of PD-1inhibitor (Tislelizumab) Plus Chemotherapy as Neoadjuvant Therapy for Limited-Stage Small-Cell Lung Cancer | unknown | Phase 2 | 15 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | May 3, 2023 | clinicaltrials |
| NCT05099237 | Enhanced Monitoring for Better Recovery and Cancer Experience in Greater Manchester(EMBRaCE-GM) | unknown | N/A | 80 | Manchester University NHS Foundation TrustOTHER_GOV | 1 |
| May 3, 2023 |
| clinicaltrials |
| NCT05840094 | Multimodalitic Imaging in the N-stage of Lung Cancer | unknown | N/A | 100 | Peking University First HospitalOTHER | 1 | May 3, 2023 | clinicaltrials |
| NCT05318807 | Personalised Diet, Exercise and Emotional Support for Lung Cancer Patients Having Chemotherapy, Radiotherapy or Immunotherapy Treatment | unknown | N/A | 30 | Imperial College Healthcare NHS TrustOTHER | 1 | May 1, 2023 | clinicaltrials |
| NCT03523468 | Curative Effect and Quality of Life Between Uniportal and Open Sleeve Lobectomy for Central Type Lung Cancer | unknown | Phase 3 | 200 | Lei JiangOTHER | 1 | Apr 25, 2023 | clinicaltrials |
| NCT03827070 | Dry Pleurodesis With Talcum and Afatinib is Used to Treat Patients With Non-Small Cell Lung Carcinoma(DPTA) | unknown | Phase 1 | 12 | Center Trials & Treatment EuropeNETWORK | 1 | Apr 25, 2023 | clinicaltrials |
| NCT05826483 | Almonertinib in the First-line Treatment of Patients of NSCLC With Poor Performance Status | unknown | Phase 1 | 20 | Guangzhou Institute of Respiratory DiseaseOTHER | 1 | Apr 24, 2023 | clinicaltrials |
| NCT03313544 | Evolution of the Heart Function When Monitoring Immunotherapies Anti-cancerous Inhibiting PD-1 | unknown | Phase 4 | 50 | Assistance Publique Hopitaux De MarseilleOTHER | 1 | Apr 21, 2023 | clinicaltrials |
| NCT04922138 | Aumolertinib Adjuvant Therapy of Resectable Stage I EGFRm+ NSCLC With High-grade Patterns(APPOINT) | unknown | Phase 2 | 104 | Baohui HanOTHER | 1 | Apr 21, 2023 | clinicaltrials |
| NCT05819905 | Radiomics for prEdiction of lunG cAncer biologY | unknown | — | 600 | Poitiers University HospitalOTHER | 1 | Apr 19, 2023 | clinicaltrials |
| NCT05258383 | Personalized Estimation of Doses Delivered During Image Guided Radiation Therapy Tests(ELISA) | unknown | — | 320 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Apr 18, 2023 | clinicaltrials |
| NCT05815472 | Advanced Patient Monitoring and A.I. Supported Outcomes Assessment in Lung Cancer Using Internet of Things Technologies (A.I. - APALITT)(APALITT) | unknown | N/A | 50 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Apr 18, 2023 | clinicaltrials |
| NCT05813522 | Furmonertinib in Patients With Leptomeningeal Metastases Associated With EGFR Mutated NSCLC | unknown | Phase 2 | 30 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Apr 14, 2023 | clinicaltrials |
| NCT03908671 | Clinical Study of Personalized mRNA Vaccine Encoding Neoantigen in Patients With Advanced Esophageal Cancer and Non-small Cell Lung Cancer | unknown | N/A | 24 | Stemirna TherapeuticsINDUSTRY | 1 | Apr 13, 2023 | clinicaltrials |
| NCT05778136 | Lung Cancer, Exercise and Force Development | unknown | N/A | 20 | Rigshospitalet, DenmarkOTHER | 1 | Apr 13, 2023 | clinicaltrials |
| NCT05810350 | Aumolertinib Combined Intrathecal Chemotherapy for Leptomeningeal Metastasis From EGFR-Mutated NSCLC and Prognostic Value of Dynamic Changes in cfDNA Profiles | unknown | Phase 2 | 40 | Three Gorges Hospital of Chongqing UniversityOTHER | 1 | Apr 13, 2023 | clinicaltrials |
| NCT05278364 | Phase I/II Study of SY-5007, a RET Inhibitor, in Patients With RET-altered Advanced Solid Tumor | unknown | Phase 1 / Phase 2 | 184 | Shouyao Holdings (Beijing) Co. LTDOTHER | 1 | Apr 12, 2023 | clinicaltrials |
| NCT05641493 | A Phase Ib/II Clinical Trial to Evaluate the Safety and Efficacy of HLX208+HLX10 in NSCLC With BRAF V600E Mutation | unknown | Phase 1 / Phase 2 | 49 | Shanghai Henlius BiotechINDUSTRY | 1 | Apr 10, 2023 | clinicaltrials |
| NCT05805956 | IMM2902 in Patients With Advanced Solid Tumors Expressing HER2 | unknown | Phase 1 / Phase 2 | 105 | ImmuneOnco Biopharmaceuticals (Shanghai) Inc.OTHER | 1 | Apr 10, 2023 | clinicaltrials |
| NCT05807022 | Evaluation of the Safety and Effectiveness of Percutaneous and Transbronchial Argon-helium Cryoablation | unknown | N/A | 60 | China-Japan Friendship HospitalOTHER | 0 | Apr 10, 2023 | clinicaltrials |
| NCT05288569 | irAE Prediction of Anti-PD-1/L1 in Lung Cancer | unknown | — | 120 | Peking Union Medical College HospitalOTHER | 1 | Apr 7, 2023 | clinicaltrials |
| NCT05802771 | Lung Cancer Multi-omics Digital Human Avatars for Integrating Precision Medicine Into Clinical Practice(LANTERN) | unknown | — | 600 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 0 | Apr 7, 2023 | clinicaltrials |
| NCT05803746 | PD-L2 Targeting Nanobody Radiotracer for PET Imaging of Solid Tumor | unknown | N/A | 20 | Peking University Cancer Hospital & InstituteOTHER | 1 | Apr 7, 2023 | clinicaltrials |
| NCT05801107 | Study to Investigate the Efficacy and Safety of WX-0593 in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients | unknown | Phase 2 | 30 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Apr 6, 2023 | clinicaltrials |
| NCT05802641 | Stereotactic Radiotherapy With Different Fractionation Modes for the Early Lung Cancer(DSBRT-1) | unknown | — | 100 | Peking University Third HospitalOTHER | 1 | Apr 6, 2023 | clinicaltrials |
| NCT04840004 | Efficacy and Safety of PVT-1 Treatment in Patients With Advanced Non-Small Cell Lung Cancer | unknown | Phase 2 | 24 | PlusVitech S.L.OTHER | 1 | Apr 5, 2023 | clinicaltrials |
| NCT05799027 | Raman Spectroscopic Analysis of Bronchoscopic Biopsy for Diagnosing Lung Cancer | unknown | N/A | 200 | China-Japan Friendship HospitalOTHER | 0 | Apr 5, 2023 | clinicaltrials |
| NCT04667793 | Clinical Study of Neoadjuvant PD-1 Antibody (Toripalimab) Plus Chemotherapy for Locally Advanced Thymic Epithelial Tumor | unknown | Phase 2 | 15 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Apr 4, 2023 | clinicaltrials |
| NCT04821570 | To Assess Immunogenicity of Coronavirus Disease 2019 (COVID-19) Vaccine in Cancer Patients Receiving Cancer Treatment(CANINE) | unknown | — | 500 | University of Kansas Medical CenterOTHER | 1 | Apr 4, 2023 | clinicaltrials |
| NCT03991403 | Study of Atezolizumab Combination Carboplatin + Paclitaxel + Bevacizumab in EGRF Mutation or ALK Translocation NSCLC | unknown | Phase 3 | 228 | Samsung Medical CenterOTHER | 1 | Apr 3, 2023 | clinicaltrials |
| NCT05769504 | Examining Clinical Trial Participation for Small Cell Lung Cancer Patients | unknown | — | 500 | Power Life Sciences Inc.INDUSTRY | 0 | Apr 3, 2023 | clinicaltrials |
| NCT05794529 | Lung Tumor Protein Synthesis Rates in Lung Cancer Patients(LungMaas) | unknown | — | 30 | Maastricht University Medical CenterOTHER | 1 | Apr 3, 2023 | clinicaltrials |
| NCT04646837 | Mechanism of Response to IMFINZI Neoadjuvant Therapy in Non-small Cell Lung Cancer Patients Based on Multiple-omics Models | unknown | Phase 1 / Phase 2 | 20 | Peking Union Medical College HospitalOTHER | 1 | Mar 29, 2023 | clinicaltrials |
| NCT04974879 | Osimertinib Combined With Bevacizumab in the Treatment Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions Metastatic Non-Small Cell Lung Cancer | unknown | Phase 2 | 20 | Qingdao Central HospitalOTHER | 1 | Mar 29, 2023 | clinicaltrials |
| NCT05104281 | Osimertinib Combined With Bevacizumab in Patients With Brain Metastasis Epidermal Growth Factor Receptor (EGFR) Mutation Positive Metastatic Non-Small Cell Lung Cancer | unknown | Phase 3 | 60 | Qingdao Central HospitalOTHER | 1 | Mar 29, 2023 | clinicaltrials |
| NCT05156515 | PD-L1 Targeting Nanobody Probe for PET Imaging of Solid Tumor | unknown | N/A | 20 | Peking University Cancer Hospital & InstituteOTHER | 1 | Mar 29, 2023 | clinicaltrials |
| NCT05789498 | Investigating the Biomarkers in Tumor and Peripheral Blood to Evaluate the Efficacy of Cancer Immunotherapy in Chest Cancer Patients | unknown | — | 60 | Zhao JunOTHER | 1 | Mar 29, 2023 | clinicaltrials |
| NCT02504346 | AZD9291, an Irreversible EGFR-TKI, in Relapsed EGFR-mutated Non-small Cell Lung Cancer Patients Previously Treated With an EGFR-TKI, Coupled to Extensive Translational Studies(TREM) | unknown | Phase 2 | 200 | Oslo University HospitalOTHER | 5 | Mar 28, 2023 | clinicaltrials |
| NCT03066271 | Pre Radiotherapy Daily Exercise Training in Non-Small Cell Lung Cancer(PRIME) | unknown | N/A | 40 | Rigshospitalet, DenmarkOTHER | 1 | Mar 28, 2023 | clinicaltrials |
| NCT05555212 | To Evaluate the Efficacy of QLH11811 in Advanced NSCLC Patients With EGFR Mutation | unknown | Phase 1 | 72 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Mar 28, 2023 | clinicaltrials |
| NCT05785208 | Efficacy Study of Osimertinib in Treatment-naïve Patients With EGFR Mutant NSCLC According to TP53 Mutational Status.(TEMPLE-2) | unknown | Phase 4 | 122 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Mar 27, 2023 | clinicaltrials |
| NCT00526396 | STAD-1 Small Cell Lung Cancer Toxicity Adjusted Dosing Study(STAD-1) | unknown | Phase 3 | 160 | National Cancer Institute, NaplesOTHER | 1 | Mar 24, 2023 | clinicaltrials |
| NCT01405586 | MILES-3: Cisplatin in Combination With Gemcitabine for Elderly Patients With Lung Cancer(MILES-3) | unknown | Phase 3 | 299 | National Cancer Institute, NaplesOTHER | 1 | Mar 24, 2023 | clinicaltrials |
| NCT01656551 | MILES-4: Study Comparing Gemcitabine and Pemetrexed, With or Without Cisplatin, in Patients With Nonsquamous Lung Cancer(MILES-4) | unknown | Phase 3 | 232 | National Cancer Institute, NaplesOTHER | 1 | Mar 24, 2023 | clinicaltrials |
| NCT02035683 | PET/CT Scan as a Tool to Rationalize the Treatment of of Advanced NSCLC Patients Undergoing First Chemotherapy(PETRA) | unknown | N/A | 220 | National Cancer Institute, NaplesOTHER | 1 | Mar 24, 2023 | clinicaltrials |
| NCT02633189 | Study Comparing Bevacizumab + Erlotinib vs Erlotinib Alone as First Line Treatment of Patients With EGFR Mutated Advanced Non Squamous Non Small Cell Lung Cancer(BEVERLY) | unknown | Phase 3 | 200 | National Cancer Institute, NaplesOTHER | 1 | Mar 24, 2023 | clinicaltrials |
| NCT03975114 | A Study Comparing Immunotherapy With Chemotherapy in the Treatment of Elderly Patients With Advanced NSCLC (MILES-5)(MILES-5) | unknown | Phase 2 | 460 | National Cancer Institute, NaplesOTHER | 1 | Mar 24, 2023 | clinicaltrials |
| NCT05782764 | A Study of Endostar Combined With Chemotherapy and Immunotherapy in Lung Squamous Cell Carcinom | unknown | Phase 4 | 30 | Xuzhou Medical UniversityOTHER | 1 | Mar 24, 2023 | clinicaltrials |
| NCT03833193 | Moderate Hypofractionated Radiotherapy for Lung Cancer | unknown | N/A | 60 | North China Petroleum Bureau General HospitalOTHER | 1 | Mar 23, 2023 | clinicaltrials |
Data updated 24 days agoSource updated May 3, 2023source: clinicaltrials